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Background: Terlipressin, as a prodrug of vasopressin, has agonistic effects on the V1 receptor and partial agonistic
effects on renal vasopressin V2 receptors. However, its effects on serum sodium concentration are controversial.
Methods: This study retrospectively investigated 127 patients with liver cirrhosis to examine the incidence and risk
factors for the decrease in serum sodium level following terlipressin administration.
Results: Terlipressin was prescribed for bleeding control (99) and management of hepatorenal syndrome (28).
Serum sodium level decreased from 134.0 ± 6.5 mmol/L to 130.4 ± 6.2 mmol/L during or after terlipressin treatment
(P < 0.001) in all patients. In 45 patients (35.4%), the serum sodium concentration decreased by > 5 mmol/L, in 29
patients (22.8%); by 5–10 mmol/L; and in 16 patients (12.6%), by > 10 mmol/L. Five patients in the latter group
showed neurological manifestations. In the univariate analysis, several factors including age, purpose of use, serum
creatinine, and Model for End-Stage Liver Disease score, representing liver function, were significantly associated
with the decrease in serum sodium after terlipressin administration. However, a multivariate analysis revealed that
only initial sodium level was the most powerful predictor of terlipressin-induced reduction in serum sodium.
Conclusion: An acute reduction in serum sodium concentration was not uncommon during terlipressin treatment,
and the baseline serum sodium level was closely related to the reduction in serum sodium concentration.
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Variceal hemorrhage and hepatorenal syndrome are very
serious complications in patients with liver cirrhosis
(Toubia & Sanyal 2008; Sanyal et al. 2008; Sass & Chopra
2009; Rahimi & Rockey 2013). Variceal hemorrhage is a
fatal condition with a high mortality rate of 24–35%; thus,
hepatorenal syndrome has a very high mortality rate of
up to 90% without liver transplantation (Bosch 1999).
Triglycyl-lysine vasopressin or glypressin (terlipressin)
is effective against variceal hemorrhage and hepatorenal
syndrome and is widely used clinically (Freeman et al.
1989; Kim 1989). As a prodrug of vasopressin, terlipressin* Correspondence: drpdj@korea.com
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in any medium, provided the original work is pis metabolized by peptidase in the tissues and is slowly
converted to vasopressin when injected intravenously
(Forsling et al. 1980; Pliska et al. 1976). Terlipressin has
agonistic effects on vasopressin V1 and V2 receptors. The
V1 receptor abundant in visceral organs is not only effect-
ive against variceal hemorrhage by triggering vasoconstric-
tion of the visceral systems and lowering the portal blood
pressure but also against hepatorenal syndrome by pre-
serving the bloodstream into the kidney.
A number of reports have indicated that terlipressin
exerts agonistic effects on the V2 receptor in kidney tubu-
lar cells primarily by increasing acuaporin-2 expression,
which, in turn, produces antidiuretic effects (Krag et al.
2008; Krag et al. 2011). However, Ferring, the manufacturer
of terlipressin, reports that the rate of risk of hyponatremia
due to this V2 receptor stimulation is < 3%. No studies
have been conducted on the clinical significance of theOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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terlipressin on blood sodium concentration for treatment of
variceal hemorrhage or hepatorenal syndrome (Krag et al.
2011; Sola et al. 2010). Therefore, no attention has been
paid to the risk of hyponatremia when using terlipressin
to treat esophageal variceal hemorrhage or hepatorenal
syndrome.
Several patients with esophageal varix and severe hypo-
natremia, probably induced by terlipressin, presented to
us. This experience posed the question as to the effects
of terlipressin on serum sodium concentrations in these
patients with liver cirrhosis, which led us to this study
that examined terlipressin-induced changes in serum
sodium concentration. We sought to identify the influ-
ential factors for hyponatremia based on a retrospective
investigation of patient medical records. We found that
terlipressin was frequently associated with hyponatremia,
and its clinical symptoms were severe in some cases.
Patients and methods
A retrospective study was conducted in a cohort of 127 pa-
tients with liver cirrhosis who were admitted to Gyeongsang
National University Hospital from January, 2004 to
December, 2011 and who received terlipressin (Glypressin,
Ferring Pharmaceuticals, Parsippany, NJ, USA) to treat
varix or hepatorenal syndrome based on their medical
records.
Among these patients, 68 (61.3%) had alcoholic
liver cirrhosis and 43 (38.7%) had viral liver cirrhosis
from various causes (type B hepatitis, type C hepatitis,
or unknown causes). Ninety-nine (78%) received
terlipressin to treat variceal hemorrhage and 22% (n = 28)
to control hepatorenal syndrome. A 2 mg initial intra-
venous injection was usually administered for variceal
hemorrhage treatment, followed by a 1 mg additional
injection at 4-h intervals for 72 h as a standard dose. In
most cases of variceal hemorrhage, an endoscopic proced-
ure was also performed for bleeding control. Although
dextrose solution was administered to most patients, some
were administered physiological saline. Some patients also
received blood. Patients with a bleeding condition were
admitted to the intensive liver treatment unit for careful
monitoring and treatment. Hepatic function, renal func-
tion, urine, and blood tests were performed in most
patients during terlipressin treatment. A 2 mg initial
dose was used to treat hepatorenal syndrome, followed
by a 1 mg intravenous injection at 6-h intervals. Serum
creatinine concentration was monitored continuously
throughout the administration period and, if the condi-
tion improved, the administration continued regardless
of the cumulative amount. Treatment was withdrawn
when serum creatinine decreased to 1.2 mg/dL, when
symptoms of peripheral circulatory failure (e.g., dermal
necrosis) occurred, or when the patient died due totheir condition worsening. Patients were also admitted
to the intensive liver treatment unit and subjected to
blood, hepatic function, renal function, and urine tests
during the treatment period.
The baseline serum sodium concentration was defined
as the result of a electrolyte test performed immediately
upon hospital admission, and its mean change was defined
as the difference shown after terlipressin administration,
based on the lowest follow-up test value obtained 2 to
5 days after terlipressin administration. The subjects were
then divided into two groups: the “decreased group”, in
whom sodium concentration decreased by > 5 mmol/L
and the “non-decreased group” who showed an un-
changed sodium concentration, a change of < 5 mmol/L,
or an increase. The study protocol was approved by the
Institutional Review Board (IRB No.: 2013-02-010).
Statistical analysis
Data are presented as means ± standard deviations. The
significance of continuous variables was tested using
an independent sample t-test, and that of categorical
variables using chi-square and Fisher’s exact tests. After div-
iding the subjects into the two groups based on changes
in serum sodium concentration following terlipressin
administration, a comparative analysis of clinical, sero-
logical, and demographic characteristics, severity of liver
damage, the purpose of terlipressin administration, and
terlipressin dose was performed. A multivariate logistic
regression analysis was used to identify significant risk
factors for a decrease in blood sodium concentration
among those identified in a simple regression analysis.
SPSS for Windows, ver. 1.2 (SPSS Inc., Chicago, IL, USA),
was used for all analyses. A value of P < 0.05 was consid-
ered to indicate statistical significance.
Results
Clinical characteristics
The basic characteristics of the entire study group are
summarized in Table 1. The mean age of the subjects was
55.6 years and there were 103 (81.1%) males. Terlipressin
was administered to 99 patients (78.0%) to control variceal
hemorrhage and to 28 (22.0%) to control hepatorenal
syndrome. An average terlipressin dose of 15.4 ± 4.4 mg
was prescribed. Total bilirubin level was 6.0 ± 7.5 mg/dL,
and prothrombin time (international normalized ratio)
was 1.8 ± 0.6. The Child–Pugh score was 8.8 ± 2.3, and
the Model for End-Stage Liver Disease (MELD) score
was 19.1 ± 10.8, reflecting higher levels of all liver func-
tion indices and indicating decreased liver function in
the trial group.
Changes in blood sodium concentrations
The mean lowest blood sodium concentration decreased
significantly (134.0 ± 6.5 vs. 130.4 ± 6.2 mmol/L, P < 0.001)







Age 53.68 ± 10.32 59.16 ± 11.87 0.008
Sex 0.098
Male (%) 70 (85.4) 33 (73.3)
Female (%) 12 (14.6) 12 (16.7)
Etiology of cirrhosis 0.745
Alcoholics (%) 48 (58.5) 25 (55.6)
Non-alcoholics (%) 34 (41.5) 20 (44.4)
Reasons of use 0.008
Bleeding control (%) 58 (70.7) 41 (91.1)
Hepatorenal syndrome
(%)
24 (29.3) 4 (8.9)
Infusion of albumin 0.203
Yes (%) 33 (40.2) 13 (28.9)
No (%) 49 (59.8) 32 (71.1)
Cumulative dose of
Terlipressin (mg)
15.38 ± 1.14 15.29 ± 4.08 0.914
Amount of hydration (L) 4.21 ± 1.99 4.70 ± 2.20 0.200
Amount of sodium infused
(mEq)




(0 ~ 1.2 mg/dL)
7.41 ± 9.72 3.33 ± 4.62 0.009
Albumin (3.4 ~ 4.8 g/dL) 2.61 ± 0.46 2.74 ± 0.54 0.164
Creatinine (0.6 ~ 1.2 mg/dL) 1.88 ± 1.75 1.20 ± 0.83 0.003
Potassium (mmol/L) 4.60 ± 1.03 4.33 ± 0.88 0.132
Hemoglobin (13 ~ 17 g/dL) 9.19 ± 2.47 9.06 ± 2.20 0.758
*PT (0.8 ~ 1.2 *INR) 1.83 ± 0.61 1.70 ± 0.62 0.253
*MELD score 21.07 ± 11.05 15.60 ± 9.52 0.004
*MELD-Na 25.95 ± 18.92 14.64 ± 11.46 0.000
Child-Pugh score (6 ~ 18) 9.24 ± 2.02 8.09 ± 2.64 0.013
Initial sodium
(135 ~ 145 mmol/L)
131.96 ± 6.84 137.84 ± 3.56 0.000
Lowest sodium
(135 ~ 145 mmol/L)
131.30 ± 6.58 128.73 ± 5.19 0.017
*PT, Prothrombin time; INR, International normalized ratio; MELD, Model for
end-stage liver disease.
Table 1 Baseline characteristics of all patients
Characteristics Value
Age 55.62 ± 11.16
Sex
Male (%) 103 (81.1)
Female (%) 24 (18.9)
Etiology of cirrhosis
Alcoholics (%) 73 (57.5)
Non-alcoholics (%) 54 (42.5)
Reasons of use
Bleeding control 99 (78.0)




Cumulative dose of Terlipressin (mg) 15.35 ± 4.43
Amount of hydration (L) 4.38 ± 2.07
Amount of sodium infused (mEq) 309.99 ± 277.55
Total bilirubin (mg/dL) 5.96 ± 7.49
Albumin (g/dL) 2.65 ± 0.49
Creatinine (mg/dL) 1.64 ± 1.52
Potassium (mmol/L) 4.51 ± 0.98
Hemoglobin (g/dL) 9.15 ± 2.37
*PT (0.8 ~ 1.2 *INR) 1.78 ± 0.62
*MELD score 19.16 ± 10.82
*MELD-Na 21.94 ± 17.48
Child-Pugh Score (6 ~ 18) 8.83 ± 2.32
Initial sodium (mmol/L) 134.04 ± 6.52
*PT, Prothrombin time; INR, International normalized ratio; MELD, Model for
end-stage liver disease.
Kang et al. SpringerPlus 2013, 2:519 Page 3 of 9
http://www.springerplus.com/content/2/1/519between baseline blood sodium concentration, measured
at the time of visiting the hospital, and those measured
2–5 days after initiation of terlipressin administration.
There were no significant changes in other hematological
profiles or the degree of liver damage after terlipressin
administration (data not shown).
An inter-group comparison of the “decreased” and “non-
decreased” groups was performed for various character-
istics (Table 2). The number of patients in the “non-
decreased” group was 82 (64.6%), and their sodium
concentration changed from 132.0 ± 6.8 to 131.3 ±
6.6 mmol/L (P = 0.017). The number of patients in the
“decreased” group was 45 (35.4%), and their sodium
concentration decreased from 137.8 ± 3.6 to 128.7 ±
5.2 mmol/L (P < 0.001). The mean ages of the patients
in the “non-decreased” and “decreased” groups were
53.7 ± 10.3 and 59.2 ± 11.9 years, respectively (P = 0.008).
Cumulative terlipressin doses in the two groups were
15.4 ± 1.1 mg and 15.3 ± 4.1 mg, respectively (P = 0.914),and the purpose of the prescription was not associated
with administration frequency. Hepatic function indices
such as bilirubin, MELD score, and Child–Pugh score in
both groups were 7.4 ± 9.7 and 3.3 ± 4.6 mg/dL (P = 0.009),
21.1 ± 11.1 and 15.6 ± 9.5 (P = 0.004), and 9.2 ± 2.0 and
8.1 ± 2.6 (P = 0.013), respectively. The baseline sodium
concentration in the groups was 132.0 ± 6.8 and 137.8 ±
6.6 mmol/L (P = 0.000) respectively (P < 0.001). The “non-
decreased” and “decreased” groups received 4.2 ± 2.0 and
4.7 ± 2.2 L of fluid, respectively, during the first 3 days
of terlipressin administration (P = 0.200). Both groups
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304.3 ± 321.0 mEq of sodium, respectively, for the first
3 consecutive days of terlipressin treatment (P = 0.864).
Figure 1 shows the trend in blood sodium concentra-
tions from baseline to those during or after terlipressin
treatment. Blood sodium concentration increased during
or after treatment in the “non-decreased” group when
compared with the baseline level in 29 patients (35.4%),
and baseline concentration was 111.0–146.1 mmol/L, which
was notably wider than the range of the “decreased” group
(113.9–138.6 mmol/L).
The subjects were divided into two groups based on
the purpose of the terlipressin prescription; i.e., bleeding
control (bleeding group) and hepatorenal syndrome treat-
ment (HRS group), and the characteristics of the groups
were compared (Table 3). The cumulative terlipressin dose
was higher in the HRS group compared with that in the
bleeding group (18.5 ± 6.1 vs. 14.5 ± 3.4 mg; P = 0.002).
The cumulative terlipressin dose, total bilirubin, cre-
atinine, blood coagulation level, MELD score, MELD-Na
score, and Child–Pugh score were also significantly higher
in the HRS group (Table 3) than in the bleeding group.
An inter-group comparison based on changes in blood so-
dium concentration among patients in the bleeding group
is summarized in Table 4. Statistically significant differ-
ences in age, Child–Pugh score, and baseline sodium
concentration were observed between the two groups.






















Figure 1 Initial and lowest sodium level of individual patient during opatients in the HRS group (Table 5). Four patients (14.3%)
showed a decrease of blood sodium concentration
by > 5 mmol/L. Baseline sodium concentration (P = 0.014)
and Child–Pugh score (P = 0.003) were significantly lower
in the “non-decreased” group than in the “decreased”
group; however, MELD score was not significantly different.
When the first day of terlipressin administration was
defined as day 1, the mean time taken for the decrease
in sodium concentration was 3.5 days; this occurred in
26 (57.8%), 12 (26.7%), and seven patients (15.5%) on
days 3, 4, and > 4 days after terlipressin administration,
respectively. In the “decreased” group, 75% (30/45) of
patients recovered their original blood sodium concen-
tration < 6 days after terlipressin withdrawal. Fifteen
patients, who failed to follow-up with blood tests to
day 6, could not be evaluated for recovery.
Sixteen patients (35.6%) in the “decreased” group showed
a decrease in blood sodium concentrations by > 10 mmol/L.
Five patients showed mental deterioration or nervous-
ness as the blood sodium concentration decreased after
terlipressin, but all of them recovered clear conscious-
ness after the blood sodium concentration was recovered.
According to a multivariate logistic regression analysis,
the strongest predictor of the decrease in blood sodium
concentration in all patients after terlipressin administra-
tion was initial serum sodium concentration (odds ratio
[OR], 1.3; 95% confidence interval [CI], 1.1–1.5; P < 0.001)














r after terlipressin treatment.
Table 3 Characteristics of two groups divided by purpose of using terlipressin
Characteristics Bleeding (n = 99) HRS (n = 28) p value
Age 57.68 ± 11.24 55.43 ± 11.08 0.918
Sex 0.480
Male (%) 79 (79.8) 24 (85.7)
Female (%) 20 (20.2) 4 (14.3)
Etiology of cirrhosis 0.967
Alcoholics (%) 57 (57.6) 16 (57.1)
Non-alcoholics (%) 42 (42.3) 12 (42.9)
Infusion of albumin 0.009
Yes (%) 30 (30.3) 16 (57.1)
No (%) 69 (69.7) 12 (42.9)
Cumulative dose of Terlipressin (mg) 14.45 ± 3.40 18.50 ± 6.04 0.002
Amount of hydration (L) 4.47 ± 1.92 4.07 ± 2.55 0.450
Amount of sodium infused (mEq) 328.87 ± 285.71 239.74 ± 237.99 0.130
Total bilirubin (0 ~ 1.2 mg/dL) 3.17 ± 4.44 15.83 ± 11.61 0.000
Albumin (3.4 ~ 4.8 g/dL) 2.66 ± 0.52 2.63 ± 0.40 0.767
Creatinine (0.6 ~ 1.2 mg/dL) 1.11 ± 0.50 3.52 ± 2.28 0.000
Hemoglobin (13 ~ 17 g/dL) 8.84 ± 2.39 10.22 ± 1.99 0.003
*PT (0.8 ~ 1.2 *INR) 1.70 ± 0.54 2.05 ± 0.78 0.032
*MELD score 15.13 ± 7.43 33.29 ± 8.90 0.000
*MELD-Na 15.61 ± 11.57 44.36 ± 16.47 0.000
Child-Pugh score (6 ~ 18) 8.19 ± 2.01 11.11 ± 1.85 0.000
Initial sodium (135 ~ 145 mmol/L) 135.74 ± 4.73 128.01 ± 8.29 0.000
Lowest sodium (135 ~ 145 mmol/L) 131.43 ± 5.57 126.73 ± 7.10 0.003
*PT, Prothrombin time; INR, International normalized ratio; MELD, Model for end-stage liver disease; HRS, Hepatorenal syndrome.
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sodium concentrations by > 10 mmol/L (OR, 1.3; 95% CI,
1.1–1.5; P = 0.012) (Table 7).
Discussion
The results showed that terlipressin administration for
variceal hemorrhage and hepatorenal syndrome frequently
lowered blood sodium concentrations. The decreases
ranged from 134.0 ± 6.5 mmol/L to 130.4 ± 6.2 mmol/L,
and 35.4% (45/127) of the patients showed a decrease in
blood sodium concentration by > 5 mmol/L. In general,
serum sodium concentration decreased to the minimum
level between days 3 and 4 after terlipressin administra-
tion was initiated. Although some factors, including age,
sex, initial sodium level, and severity of liver damage
were significantly different between the “decreased” and
“non-decreased” groups, the multivariate analysis indi-
cated that only higher baseline serum sodium concen-
tration was significant for a decreased sodium level.
Similarly, in the group in which serum sodium concen-
tration decreased by > 10 mmol/L, the baseline serum
sodium concentration was the only factor that was asso-
ciated with serum sodium concentration.In a study on the effects of terlipressin to treat blood so-
dium concentration of patients with variceal hemorrhage,
(Sola et al. 2010) reported that MELD score and baseline
blood sodium concentration were important factors. How-
ever, that study had limitations in that it focused only on
patients with variceal hemorrhage and included no more
than 58 subjects, which may have been insufficient for a
multivariate analysis. Another limitation was that despite
the small number of subjects, they were divided into three
groups. If more subjects had been involved, the MELD
score might not have been an influential factor. Our
data may be more meaningful because we included 127
patients, approximately twice the number of the sub-
jects in the study of Sola and co-workers, and patients
with hepatorenal syndrome were included.
(Sola et al. 2010) found that terlipressin decreased
blood sodium concentration by > 5 mmol/L in 67% of the
patients and by > 10 mmol/L in 31%. This is more than
the 35.4% occurrence rate in the present study. They
divided subjects into three groups and found no differ-
ence in the cumulative dose of terlipressin among the
groups; however, the average cumulative dose was 28 mg,
which was almost twice that (15 mg) used in this study.
Table 4 Clinical data and laboratory tests in patients of the bleeding group categorized according to changes in serum
sodium concentratio
Characteristics Non-decreased (n = 58) Decreased (n = 41) p value
Age 53.66 ± 10.14 58.54 ± 12.20 0.039
Sex 0.167
Male (%) 49 (84.5) 30 (73.2)
Female (%) 9 (15.5) 11(26.8)
Etiology of cirrhosis 0.507
Alcoholics (%) 35 (60.3) 22 (53.7)
Non-alcoholics (%) 23 (39.7) 19 (46.3)
Infusion of albumin 0.282
Yes (%) 20 (34.5) 10 (24.4)
No (%) 38 (65.5) 31 (75.6)
Cumulative dose of Terlipressin (mg) 14.21 ± 3.42 14.80 ± 3.39 0.391
Amount of hydration (L) 4.34 ± 1.77 4.64 ± 2.13 0.447
Amount of sodium infused (mEq) 341.25 ± 259.89 313.77 ± 321.40 0.652
Total bilirubin (0 ~ 1.2 mg/dL) 3.72 ± 5.37 2.44 ± 2.63 0.122
Albumin (3.4 ~ 4.8 g/dL) 2.60 ± 0.49 2.75 ± 0.55 0.162
Creatinine (0.6 ~ 1.2 mg/dL) 1.17 ± 0.51 1.03 ± 0.47 0.163
Hemoglobin (13 ~ 17 g/dL) 8.64 ± 2.46 9.12 ± 2.28 0.328
*PT(0.8 ~ 1.2 *INR) 1.79 ± 0.61 1.58 ± 0.41 0.057
*MELD score 16.17 ± 7.63 13.66 ± 6.97 0.098
*MELD-Na 17.50 ± 12.67 12.93 ± 9.31 0.052
Child-Pugh score (6 ~ 18) 8.60 ± 1.75 7.61 ± 2.23 0.015
Initial sodium (135 ~ 145 mmol/L) 134.22 ± 4.93 137.91 ± 3.46 0.000
Lowest sodium (135 ~ 145 mmol/L) 133.21 ± 5.14 128.90 ± 5.20 0.000
*PT, Prothrombin time; INR, International normalized ratio; MELD, Model for end-stage liver disease.
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may explain the number of patients with a difference
of > 5 mmol/L in serum sodium concentration.
Another study, which reported that terlipressin lowers
blood sodium concentration, found that the duration
of terlipressin treatment is closely associated with the
decrease in serum sodium concentration (Bruha et al.
2009; Krag et al. 2010). Therefore, these studies sup-
port the notion that even short-term use of terlipressin,
as recently suggested, is effective for controlling variceal
hemorrhage and preventing decreases in blood sodium
concentrations (Lo et al. 2009). However, according to
(Sola et al. 2010), the blood sodium concentration had
decreased by > 5 mmol/L in 50% of the patients and
by > 10 mmol/L in 16% 48 h after terlipressin adminis-
tration was initiated (Krag et al. 2011), which coincides
with our finding that blood sodium concentration de-
creased by > 5 mmol/L in 57.8% of the patients 3 days
after initiation of terlipressin treatment. This result sug-
gests that even short-term use of terlipressin can reduce
blood sodium concentration. Therefore, electrolyte tests
should be carried out in patients receiving terlipressin.Our data suggest that some liver function indices, such
as the MELD and Child–Pugh scores, were negatively
correlated with blood sodium concentrations. This result
is consistent with the observation that hyponatremia
frequently accompanies deteriorated liver function. An-
other study showed that both lower MELD score (OR,
0.9; 95% CI, 0.8–1.0, P < 0.05) and higher baseline blood
sodium concentration (OR, 1.10; 95% CI, 1–1.2, P < 0.05),
which were significant factors in a multivariate analysis,
led to a greater decrease in blood sodium concentration
after terlipressin administration (Sola et al. 2010), whereas
our study showed that initial sodium concentration was
the sole factor. However, we believe that the MELD score
had only weak statistical power in that study, because the
95% CI included “1.0”. In the present study, although the
severity of liver function damage showed associations in
the simple comparison, these might not have been evident
in the multivariate analysis because initial sodium level
was so strong factor that other ones might seem to have
not influence on the change of sodium level.
The pathological mechanism of hepatorenal syndrome
involves splanchinic arterial dilation, which decreases the
Table 5 Clinical data and laboratory tests on patients with HRS categorized according to changes in serum
sodium concentration
Characteristics Non-decreased (n = 24) Decreased (n = 4) p value
Age 53.75 ± 10.97 65.50 ± 4.93 0.006
Sex 0.508
Male (%) 21 (87.5) 3 (75.0)
Female (%) 3 (12.5) 1(25.0)
Etiology of cirrhosis 0.436
Alcoholics (%) 13 (54.2) 3 (75.0)
Non-alcoholics (%) 11 (45.8) 1 (25.0)
Infusion of albumin 0.436
Yes (%) 13 (54.2) 3 (75.0)
No (%) 11 (45.8) 1 (25.0)
Cumulative dose of Terlipressin (mg) 18.21 ± 5.92 20.25 ± 7.41 0.541
Amount of hydration (L) 3.87 ± 2.45 5.28 ± 3.21 0.317
Amount of sodium infused (mEq) 245.18 ± 242.31 207.10 ± 240.77 0.773
Total bilirubin (0 ~ 1.2 mg/dL) 16.39 ± 11.97 12.50 ± 9.93 0.545
Albumin (3.4 ~ 4.8 g/dL) 2.63 ± 0.45 2.68 ± 0.46 0.824
Creatinine (0.6 ~ 1.2 mg/dL) 3.61 ± 2.39 2.94 ± 1.56 0.617
Hemoglobin (13 ~ 17 g/dL) 10.53 ± 1.95 8.40 ± 1.12 0.045
*PT(0.8 ~ 1.2 *INR) 1.91 ± 0.63 2.88 ± 1.15 0.190
*MELD score 32.92 ± 8.87 35.50 ± 10.08 0.600
*MELD-Na 46.38 ± 15.72 32.25 ± 17.86 0.114
Child-Pugh score (6 ~ 18) 10 .79 ± 1.79 13.00 ± 0.81 0.003
Initial sodium (135 ~ 145 mmol/L) 126.50 ± 7.78 137.12 ± 5.11 0.014
Lowest sodium (135 ~ 145 mmol/L) 126.69 ± 7.44 126.98 ± 5.43 0.943
* PT, Prothrombin time; INR, International normalized ratio; MELD, Model for end-stage liver disease; HRS, Hepatorenal syndrome.
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renovascular contraction, which is characterized by de-
creased urination and dilutional hepatorenal syndrome
(Ackermann 2009; Bosma et al. 2010; Testro & Angus 2009;
Oliver & Verna 2009). Few studies have been conducted on




Purpose of use 0.746 1.423
Initial sodium (mmol/L) 0.000 1.299
Infusion of albumin 0.227 0.543
Child-Pugh score 0.229 0.844
Total bilirubin (mg/dL) 0.488 0.959
Creatinine (mg/dL) 0.428 0.727
*MELD score 0.081 1.106
*OR, Odds ratio; MELD, Model for end-stage liver disease.the frequency of hyponatremia after the use of terlipressin
for hepatorenal syndrome was 10% (Nazar et al. 2010),
which was considerably lower than that of variceal
hemorrhage. Although the number of patients was small,
the baseline blood sodium concentration in patients
with hepatorenal syndrome was 128 mmol/L, which wasduced serum sodium reduction (> 5 mmol/L) in all patients











Table 7 Independent risk factors for terlipressin induced serum sodium decrease (>10 mmol/L) in all patients
p value *OR 95% confidence interval [CI] for OR
Lower Upper
Age 0.335 1.028 0.972 1.088
Sex 0.828 1.186 0.253 5.551
Purpose of use 0.768 0.635 0.031 12.949
Initial sodium (mmol/L) 0.012 1.276 1.055 1.542
Infusion of albumin 0.701 1.298 0.344 4.894
Child-Pugh score 0.159 0.767 0.530 1.110
Total bilirubin (mg/dL) 0.457 0.934 0.780 1.118
Creatinine (mg/dL) 0.195 0.284 0.042 1.908
*MELD score 0.028 1.216 1.022 1.448
*OR, odds ratio; MELD, Model for end-stage liver disease.
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variceal hemorrhage who received the same treatment.
The V2 vasopressin receptor may be already saturated
in patients with hepatorenal syndrome due to full acti-
vation by endogenous hormones. Therefore, terlipressin
administration may limit the effects of these hormones,
resulting in smaller changes in serum sodium concen-
tration. In the present study, there was significant differ-
ence between bleeding group and HRS group in terms
of the decrease in serum sodium concentration (41% vs
14%), although use of purpose was not a significant
predictor in the multivariate analysis.
Studies of the side-effects of terlipressin and its effi-
cacy in combination with somatostatin against variceal
hemorrhage reported that terlipressin induces hyponatremia
only rarely (Escorsell et al. 2000; Feu et al. 1996; Walker
et al. 1997). In these studies, no effect of terlipressin on
blood sodium concentration was detected, because hypo-
natremia was defined as < 130 mmol/L sodium and the
baseline sodium concentration was not mentioned. In
the present study, the baseline sodium concentration
and changes in blood sodium concentration during
the follow-up period were evaluated, and a difference
of > 5 mmol/L was used as the criterion for hyponatremia.
Therefore, our study is a more reasonable evaluation of
the effect of terlipressin on changes in blood sodium
concentrations.
The limitations of this study are its retrospective co-
hort design, it was not controlled, and factors that could
affect blood sodium concentration were not controlled
for. Fluid administration may have an effect on the re-
sults. The effects of fluid volume and type on blood sodium
concentration cannot be ignored. Because the amount of
sodium supplied was roughly estimated based on prescrip-
tion data in the medical records and the timing of admis-
sion to the hospital, the actual result may be substantially
different from the volume of fluid and the amount of so-
dium administered. However, our conclusions remain validbecause treatment practices at any single institution are
usually consistent, and more objective data, such as blood
test results, were available.
In conclusion, terlipressin is used to treat variceal
hemorrhage and hepatorenal syndrome, two serious
complications of liver cirrhosis, but often results in a de-
creased blood sodium concentration. Since hyponatremia
occurs a relatively short time after terlipressin administra-
tion, it is necessary to start electrolyte testing at the initial
stage and to monitor possible neurological symptoms of
hyponatremia. Similarly, care must be taken during ad-
ministration of terlipressin to patients with a high base-
line blood sodium concentration, since this is associated
with a decreased blood sodium concentration.
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